We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioTelemetry (BEAT) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
BioTelemetry (BEAT - Free Report) closed the most recent trading day at $66.73, moving -0.58% from the previous trading session. This change lagged the S&P 500's daily loss of 0.02%. Meanwhile, the Dow lost 0.03%, and the Nasdaq, a tech-heavy index, lost 0.21%.
Coming into today, shares of the heart monitoring device maker had gained 1.37% in the past month. In that same time, the Medical sector lost 3.97%, while the S&P 500 lost 1.4%.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. This is expected to be February 28, 2019. The company is expected to report EPS of $0.42, up 31.25% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $103.02 million, up 12.29% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for BEAT. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BEAT is holding a Zacks Rank of #1 (Strong Buy) right now.
Valuation is also important, so investors should note that BEAT has a Forward P/E ratio of 37.71 right now. Its industry sports an average Forward P/E of 19.62, so we one might conclude that BEAT is trading at a premium comparatively.
Meanwhile, BEAT's PEG ratio is currently 3.77. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BEAT's industry had an average PEG ratio of 1.57 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 112, which puts it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioTelemetry (BEAT) Dips More Than Broader Markets: What You Should Know
BioTelemetry (BEAT - Free Report) closed the most recent trading day at $66.73, moving -0.58% from the previous trading session. This change lagged the S&P 500's daily loss of 0.02%. Meanwhile, the Dow lost 0.03%, and the Nasdaq, a tech-heavy index, lost 0.21%.
Coming into today, shares of the heart monitoring device maker had gained 1.37% in the past month. In that same time, the Medical sector lost 3.97%, while the S&P 500 lost 1.4%.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. This is expected to be February 28, 2019. The company is expected to report EPS of $0.42, up 31.25% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $103.02 million, up 12.29% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for BEAT. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BEAT is holding a Zacks Rank of #1 (Strong Buy) right now.
Valuation is also important, so investors should note that BEAT has a Forward P/E ratio of 37.71 right now. Its industry sports an average Forward P/E of 19.62, so we one might conclude that BEAT is trading at a premium comparatively.
Meanwhile, BEAT's PEG ratio is currently 3.77. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BEAT's industry had an average PEG ratio of 1.57 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 112, which puts it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.